Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Future directions and challenges in harnessing NK cells against Acute Myeloid Leukemia

Future directions and challenges in harnessing NK cells against Acute Myeloid Leukemia

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

Study shows CAR T-cell therapy's risk of second primary malignancies comparable to other treatments

Study shows CAR T-cell therapy's risk of second primary malignancies comparable to other treatments

UC's Eric Vick receives major grants to advance research into combination therapy for leukemia

UC's Eric Vick receives major grants to advance research into combination therapy for leukemia

Investigating inflammatory memory in hematopoietic stem cells within the AML niche

Investigating inflammatory memory in hematopoietic stem cells within the AML niche

Leukemia cells depend on P-bodies for growth and survival

Leukemia cells depend on P-bodies for growth and survival

Breakthrough in acute myeloid leukemia treatment targets stem cells

Breakthrough in acute myeloid leukemia treatment targets stem cells

DDX41: A unique player in myeloid leukemogenesis

DDX41: A unique player in myeloid leukemogenesis

Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia

Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia

Targeted gene therapy may reduce AML burden and protect the heart from cardiotoxicity

Targeted gene therapy may reduce AML burden and protect the heart from cardiotoxicity

Metformin use linked to reduced risk of myeloproliferative neoplasms

Metformin use linked to reduced risk of myeloproliferative neoplasms

AML patients at the extremes of older age derive benefit from VEN-HMA regimen

AML patients at the extremes of older age derive benefit from VEN-HMA regimen

Medically aided conception vs. natural conception: Study explores cancer risk in children

Medically aided conception vs. natural conception: Study explores cancer risk in children

Novel vaccine approach targets AML and other blood cancers

Novel vaccine approach targets AML and other blood cancers

Urine-based test developed for early detection of head and neck tumors

Urine-based test developed for early detection of head and neck tumors

NCCN 2024 Annual Conference focuses on practical applications for improving cancer care

NCCN 2024 Annual Conference focuses on practical applications for improving cancer care

Innovative cancer treatment approach yields promising results in pediatric patients

Innovative cancer treatment approach yields promising results in pediatric patients

Study shows GHRH antagonist's role in AML drug resistance

Study shows GHRH antagonist's role in AML drug resistance

Research identifies how leukemia develops resistance to first line treatments

Research identifies how leukemia develops resistance to first line treatments

Longer durations of breastfeeding lowers the risk of childhood cancers

Longer durations of breastfeeding lowers the risk of childhood cancers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.